Previous 10 | Next 10 |
Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy - Analysis of Five-Year Results Presented at 50th Child Neurology Society Annual Meeting - PR Newswire SOUTH PLAINF...
PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program PR Newswire SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to...
STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy - Translarna was seen to slow disease progression compared to standard of care alone - - Data from long-term, real-world results f...
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of ...
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community - Patient Advocacy Organizations in Brazil and the U.K. Awarded Funding - PR Newswire SOUTH PLAINFIELD, N.J. , Sept. 7, 2021 /PRNewswire/ -- PTC Th...
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome - Approval Addresses Unmet Needs of Patients with No Other Treatment Options - PR Newswire SOUTH PLAINFIELD, N.J. , Aug. 23, 2021 /PRNewswi...
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency - Commentary Published in the European Molecular Biology Organization Journal - PR Newswire SOUTH PLAINFIELD, N.J. , Aug. 2...
PTC Therapeutics, Inc. (PTCT) Q2 2021 Earnings Conference Call July 29, 2021 04:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President, Global Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Development Officer Eric Pauwels - Chief B...
PTC Therapeutics (NASDAQ:PTCT): Q2 GAAP EPS of -$1.68 beats by $0.13. Revenue of $116.7M (+55.1% Y/Y) beats by $6.42M. Press Release For further details see: PTC Therapeutics EPS beats by $0.13, beats on revenue
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress a...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....